Recommencement of atezolizumab with associated pulmonary sarcoid‐like reaction

Abstract

AbstractAn 81 year old male with Child‐Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated with 3‐weekly atezolizumab and bevacizumab developed a pulmonary sarcoid‐like reaction (SLR) after 5 months. Atezolizumab, an immune checkpoint inhibitor, was identified as the likely culprit. He was treated with prednisolone, resulting in improvement, and was successfully rechallenged with both atezolizumab and bevacizumab.